NASDAQ:XRTX XORTX Therapeutics (XRTX) Stock Price, News & Analysis $1.10 +0.04 (+3.77%) Closing price 04:00 PM EasternExtended Trading$1.08 -0.02 (-1.36%) As of 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsOwnershipSEC Filings About XORTX Therapeutics Stock (NASDAQ:XRTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get XORTX Therapeutics alerts:Sign Up Key Stats Today's Range$0.92▼$1.1150-Day Range$0.92▼$2.4852-Week Range$0.83▼$3.65Volume39,167 shsAverage Volume612,433 shsMarket Capitalization$2.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview XORTX Therapeutics Inc. is a clinical-stage pharmaceutical company focused on developing therapies for diseases associated with abnormal uric acid metabolism and kidney dysfunction. The company’s research centers on inhibiting xanthine oxidase, an enzyme involved in uric acid production, with the goal of reducing kidney injury and slowing disease progression. XORTX’s lead development program, XRx-008, is being investigated as a potential treatment for autosomal dominant polycystic kidney disease, a genetic disorder that can progressively impair kidney function. The company has also described additional programs involving its uric acid-lowering platform for acute kidney injury and other conditions linked to kidney disease and metabolic dysfunction. Based in Calgary, Alberta, Canada, XORTX serves the global pharmaceutical and biotechnology market through drug development activities and collaborations. The company’s programs remain in clinical development, and its product candidates have not necessarily received regulatory approval for commercial sale.AI Generated. May Contain Errors. Read More XORTX Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreXRTX MarketRank™: 0.40709677419 of 5 starsXORTX Therapeutics scored higher than 8% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingXORTX Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageXORTX Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about XORTX Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of XORTX Therapeutics is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of XORTX Therapeutics is -0.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXORTX Therapeutics has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about XORTX Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted14.01% of the float of XORTX Therapeutics has been sold short.Short Interest Ratio / Days to CoverXORTX Therapeutics has a short interest ratio ("days to cover") of 0.08, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in XORTX Therapeutics has recently increased by 285.22%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXORTX Therapeutics does not currently pay a dividend.Dividend GrowthXORTX Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.26 News SentimentXORTX Therapeutics has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for XORTX Therapeutics this week, compared to 2 articles on an average week.Search Interest8 people have searched for XRTX on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.MarketBeat Follows2 people have added XORTX Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, XORTX Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders6.90% of the stock of XORTX Therapeutics is held by insiders.Percentage Held by Institutions0.23% of the stock of XORTX Therapeutics is held by institutions.Read more about XORTX Therapeutics' insider trading history. Receive XRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XORTX Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XRTX Stock News HeadlinesXORTX Therapeutics Inc XRTXOctober 16, 2026 | morningstar.comMXORTX Plans Canadian Trial Of Gout Drug XORLO To Support Future U.S. NDA Filing; Stock UpOctober 9, 2026 | rttnews.comManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 in one quarter. Institutions own about 83% of shares, including BlackRock's 32 million shares worth $716 million and Vanguard's 48 million shares worth nearly $1.1 billion. A new multi-year deal with Palantir adds an AI-driven edge to this energy producer's operations.October 27 at 1:00 AM | Monument Traders Alliance (Ad)Xortx Therapeutics Shares Rise After Company Reports Potential Partner Interest for Gout ProgramOctober 8, 2026 | finance.yahoo.comXORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for GoutOctober 8, 2026 | financialpost.comFXORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO(TM), Targeting USD$700M+ U.S. Gout Market OpportunitySeptember 19, 2026 | barrons.comXORTX Therapeutics Shares Rise 12% On IND Submission PlanSeptember 19, 2026 | rttnews.comXORT Targets FDA IND Filing For XRx-026 Gout Program; NDA Submission Planned Within A YearSeptember 18, 2026 | rttnews.comSee More Headlines XRTX Stock Analysis - Frequently Asked Questions How have XRTX shares performed this year? XORTX Therapeutics' stock was trading at $2.81 at the start of the year. Since then, XRTX shares have decreased by 60.9% and is now trading at $1.10. How were XORTX Therapeutics' earnings last quarter? XORTX Therapeutics Inc. (NASDAQ:XRTX) issued its earnings results on Saturday, August, 15th. The technology company reported ($1.05) earnings per share (EPS) for the quarter. When did XORTX Therapeutics' stock split? Shares of XORTX Therapeutics reverse split before market open on Monday, April 6th 2026.The 1-5 reverse split was announced on Wednesday, April 1st 2026. The number of shares owned by shareholders was adjusted after the market closes on Friday, April 3rd 2026. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. How do I buy shares of XORTX Therapeutics? Shares of XRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/15/2026Today10/27/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (16m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 XRTX's financial health is in the Red zone, according to TradeSmith. XRTX has been in this zone for over 16 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:XRTX CIK1729214 Webwww.xyratex.com Phone+44-23-92496000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($2.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$2.66 million Net MarginsN/A Pretax MarginN/A Return on Equity-137.85% Return on Assets-108.16% Debt Debt-to-Equity RatioN/A Current Ratio3.58 Quick Ratio3.58 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.50 per share Price / Book0.73Miscellaneous Outstanding Shares1,820,000Free Float1,692,000Market Cap$2.00 million OptionableNot Optionable Beta0.78 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:XRTX) was last updated on 10/27/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XORTX Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share XORTX Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
